Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1989;25(1):70-2.
doi: 10.1007/BF00694342.

Tubular nephrotoxicity during long-term ifosfamide and mesna therapy

Affiliations

Tubular nephrotoxicity during long-term ifosfamide and mesna therapy

M P Goren et al. Cancer Chemother Pharmacol. 1989.

Abstract

The nephrotoxic effects of ifosfamide were assessed in 18 children and adolescents given cumulative doses of 32-112 g/m2 (1.6 g/m2 per day in sequential 5-day courses) with the uroprotectant mesna (1.2 g/m2 per day). Tubular nephrotoxicity was evaluated by measuring the urinary concentrations of N-acetyl-beta-D-glucosaminidase (NAG), alanine aminopeptidase (AAP), and total protein before and during sequential courses of therapy. Of 15 patients who had normal levels of tubular markers before ifosfamide therapy, only 1 developed a persistent increase in baseline values of the three tubular markers with the sixth course of ifosfamide. Although transient increases in the excretion of these markers were observed during each 5-day course of ifosfamide, the magnitude did not increase over sequential courses in these 15 patients. Of the remaining three patients who had increased NAG levels before ifosfamide therapy, two showed a progressive increase in enzymuria and proteinuria, and serum creatinine concentrations increased in a single patient who had obstructive uropathy. Our data suggest that children with normal renal function can be given large cumulative amounts of ifosfamide in fractionated doses with little risk of progressive clinical nephrotoxicity.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Cancer. 1989 Feb 15;63(4):649-51 - PubMed
    1. Cancer Treat Rep. 1987 Feb;71(2):127-30 - PubMed
    1. J Natl Cancer Inst. 1988 Jun 15;80(8):556-66 - PubMed
    1. Cancer Treat Rep. 1985 May;69(5):499-504 - PubMed
    1. Cancer Treat Rep. 1980 Oct-Nov;64(10-11):1103-8 - PubMed

Publication types

MeSH terms

LinkOut - more resources